FOCUS REVIEWS ON HEART FAILURE : Current Evidence of the Efficacy of Cell-Based Therapies in Heart Failure

DOI Web Site Web Site PubMed 参考文献33件
  • Harvey Emma
    Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford Stem Cell Research Laboratory, NHS Blood and Transplant
  • Fisher Sheila A.
    Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford Systematic Review Initiative, NHS Blood and Transplant
  • Doree Carolyn
    Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford Systematic Review Initiative, NHS Blood and Transplant
  • Taggart David P.
    Nuffield Department of Surgical Sciences, University of Oxford
  • Martin-Rendon Enca
    Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford Stem Cell Research Laboratory, NHS Blood and Transplant

書誌事項

タイトル別名
  • Current Evidence of the Efficacy of Cell-Based Therapies in Heart Failure

この論文をさがす

抄録

Heart failure (HF) is the major cause of mortality worldwide. For more than a decade, cell-based therapies have been developed as treatment for heart disease as an alternative to current therapies. Trials and systematic reviews have assessed the safety and efficacy of cell therapies in a diverse number of participants and clinical settings. The present study collated and synthesized evidence from all systematic reviews related to cell-based therapies and HF. A total of 11 systematic reviews were identified through searches of electronic databases up to June 2014. We set out to answer 2 key questions on the efficacy of cell therapies in HF: (1) What is the overall effect of cell therapies on primary outcomes such as left ventricular ejection fraction (LVEF) and mortality? (2) How important is it to define the clinical setting and length of follow-up when assessing cell therapies and HF? There seems to be enough evidence to suggest that cell therapies have a moderate, long-lasting effect on LVEF, but the reduction on the risk of mortality observed by some systematic reviews needs to be confirmed in larger, statistically powered clinical trials. Additionally, and in order to strengthen conclusions, it is important to assess clinical evidence for defined clinical settings and to standardize the length of follow-up when comparing outcome data across several trials and systematic reviews. (Circ J 2015; 79: 229–236)

収録刊行物

  • Circulation Journal

    Circulation Journal 79 (2), 229-236, 2015

    一般社団法人 日本循環器学会

参考文献 (33)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ